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SUMMARY
This study evaluated the usefulness of the anti-HBc, hepatitis C virus antibodies (anti-HCV), human T cell lymphotropic virus I
and II antibodies (anti-HTLV I/II), serologic tests for syphilis, and surface antigen of hepatitis B virus (HBsAg) as surrogate markers
for the risk for HIV infection in 80,284 serum samples from blood donors from the Blood Bank of “Hospital Universitário Regional
Norte do Paraná”, Londrina, Paraná State, Brazil, analyzed from July 1994 to April 2001. Among 39 blood donors with positive
serology for HIV, 12 (30.8%) were anti-HBc positive, 10 (25.6%) for anti-HCV, 1 (2.6%) for anti-HTLV I/I, 1 (2.6%) was positive for
syphilis, and 1 (2.6%) for HBsAg. Among the donors with negative serology for HIV, these markers were detected in 8,407 (10.5%),
441 (0.5%), 189 (0.2%), 464 (0.6%), and 473 (0.6%) samples, respectively. The difference was statistically significant (p < 0.001)
for anti-HBc and anti-HCV. Although the predictive positive value for these surrogate markers were low for HIV infection, the results
confirmed the anti-HBc and anti-HCV as useful surrogate markers for HIV infection thus reinforcing the maintenance of them in
the screening for blood donors contributing to the prevention of the small number of cases in which HIV is still transmitted by
transfusion.
KEYWORDS: Surrogate markers; Human immunodeficiency virus infection (HIV); Blood donors; Serological screening; Anti-
HBc; Anti-HCV .
INTRODUCTION
In industrialized countries, the use of sensitive human
immunodeficiency virus (HIV) screening tests, donor deferral, and more
conservative use of blood have resulted in a dramatic decrease in the
transmission of HIV infection by blood transfusion. The risk of HIV
transmission in the United States by blood screened negative for HIV
antibody was recently estimated at one in 440,000-660,000 donations.
However, in many developing countries where the prevalence of HIV
infection among blood donors is orders of magnitude greater than in
industrialized countries, an estimated 5 to 10% of HIV infections are
due to blood transfusion10. More strategies and measures to improve the
effectiveness of the routine screening of blood donors and the safety of
the blood components have been evaluated.
The rate of hepatitis B virus (HBV) infection in HIV infected patients
is 10-30 times higher then in general population from United States19.
During the HBV infection, the HBV produces envelope protein or surface
antigen (HBsAg) in vast excess during the period before seroconversion.
For this reason, antigen tests with sufficient sensitivity were available
for blood donation screening at a very early stage. With exposure to the
neutralizing anti-HBs antibodies, the HBsAg disappears. The core particle
of the hepatitis B virus (HBcAg) is an extremely potent antigen that
elicits strong B- and T-cell responses in individuals exposed to the virus.
The antibody to core antigen (anti-HBc) occurs early in acute infection,
4-10 weeks after appearance of surface antigen of hepatitis B virus
(HBsAg), usually persists longer, or for lifetime, than other hepatitis B
virus (HBV) markers, is associated with an elevated risk of transmission
of non-A non-B hepatitis and has been used as a surrogate to screen
blood donors14,20. Anti-HBc was introduced in routine donor screening
in 1987 in an attempt to identify donors at risk of transmitting post-
transfusion non-A non-B hepatitis13. Anti-HBc detects persons who have
been previously infected with HBV and can therefore serve as surrogate
test for other infectious agents. In addition to indicating previous exposure
to HBV, the anti-HBc assays have been used as surrogate marker for the
presence of other infectious agents. In some blood banks in regions of
high prevalence of HIV infection, the anti-HBc was implemented as a
surrogate test for HIV infection9. Exclusion of anti-HBc positive donors
reduces the incidence of post-transfusion hepatitis and possibly other
virus infection, such as HIV infection, due the frequency of dual infection.
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The rate of anti-HBc among blood donors in the United Sates ranged
from 1.0%6 to 1.5%9. The anti-HBc is present without other serologic
markers and with normal alanine aminotransferase (ALT) in 2% of routine
blood donors in the United States; 70% of these are due to recovery
from subclinical HBV infection, and may be infectious, and the rest are
considered false-positive19. In Brazil, anti-HBc ant ALT were introduced
in blood donor screening in November 199314. The prevalence of anti-
HBc among blood donors in Brazil ranged from 5.40% to 18.18%,
according to different regions of the country14.
The discovery of hepatitis C virus (HCV) in 19893 and the subsequent
introduction of specific screening tests for anti- HCV have reduced the
rate of 90% of post-transfusion hepatitis infection. The anti-HCV
antibodies are detected from 12 to 20 weeks after the onset of clinical
signs and symptoms. During this phase, antibodies have not yet a chance
to develop, but infectious virus is already prevalent in blood14. After the
discovery of the HCV, the agent of 90% of transfusional non-A non-B
hepatitis, the maintenance of anti-HBc and ALT was questioned. In 1995,
the National Institute of Health (NIH) of the United States recommended
the maintenance of the anti-HBc test because of its potential to prevent
some cases of post-transfusional HBV hepatitis, it acts as a surrogate
marker for HIV infection in blood donors and could decrease the residual
risk of the HIV infection transmitted by blood transfusion1,14. In the
absence of consistent studies that would permit the exclusion of the anti-
HBc and ALT tests, many countries such as the United States, France,
and Brazil have maintained these tests in the serologic screening of blood
donors14.
In 1972, American institutions recommended eliminating serologic
test for syphilis (STS) screening of blood donors because of its limited
public health value, but the recommendation was not implemented. In
1983, the STS was reevaluated, and the Food and Drug Administration
(FDA) decided to retain it because of its potential value as a marker of
behavior placing subjects at risk for HIV infection. However, no large
study has established that the STS is a valuable marker of HIV infection
among blood donors6.
The human T cell lymphotropic virus I and II (HTLV I/II) can be
transmitted by blood and cellular blood products, maternal milk, sexual
contact and by the shared use of syringes and needles among intravenous
drugs abusers18. Rates of prevalence of anti-HTLV I/II among patients
with acquired immunodeficiency syndrome, homosexual men, HIV
infected patients and intravenous drug users are registered4,18. In this
study, we evaluated the importance of surrogate markers such as anti-
HBc, anti-HCV, anti-HTLV I/II antibodies, serologic test for syphilis
(STS), and HBsAg for the risk for HIV infection among blood donors.
MATERIAL AND METHODS
Serum samples: This study was a retrospective evaluation of the
serologic results of anti-HIV, anti-HBc, anti-HCV and anti-HTLV I/II
antibodies, STS, and the presence of HBsAg obtained in 80,284 serum
samples from blood donors of the Blood Bank of “Hospital Universitário
Regional Norte do Paraná”, Londrina, southern region of Brazil, assayed
from July 1994 to April 2001.
Routine laboratory procedures: All the donations were tested for
infectious diseases as required by the national advisory recommendations.
The tests performed were for anti-HBc by enzyme linked immunosorbent
assay (ELISA, Abbott Laboratories and Organon Teknika), anti-HCV
and HBsAg by microparticle enzyme linked immunosorbent assay third-
generation (MEIA, Abbott Laboratories), anti-HTLV I/II was assayed
by ELISA (Embrabio, São Paulo), screening tests for anti-HIV types 1
and 2 (viral lysate and recombinant antigens) by ELISA (Abbott
Laboratories, Organon Teknika, Behring Institute, Sanofi Pasteur) and
confirmatory tests (indirect immunofluorescence and/or Western Blot)
supported by Laboratório Central (LACEN, Curitiba, PR, Brazil). The
STS used was the Venereal Disease Research Laboratories test (VDRL,
Laborclin, Pinhais, PR, Brazil).
Statistical Analysis: It was assessed the prevalence, sensitivity,
positive predictive value (PPV), and relative prevalence (RP) of the
surrogate markers assayed, with 95% confidence interval (CI). For the
analyses of the results, the Fisher Exact Test (p < 0.001) was used.
RESULTS
The overall prevalence of the serologic markers assayed is shown in
Table 1. Thirty-nine donations (0.05%) were anti-HIV reactive, 8,419
(10.50%) anti-HBc reactive, 451 (0.56%) anti-HCV positive, 190 (0.24%)
anti-HTLV I/II positive, 465 (0.58%) STS reactive, and 474 (0.59%)
HBsAg reactive.
The results of the relationship between the anti-HIV results and the
serologic surrogate markers of anti-HBc, anti-HCV, anti-HTLV I/II, STS,
and the presence of HBsAg showed that among 39 blood donors with
positive serology for anti-HIV, 12 (30.80%) were anti-HBc positive, 10
(25.60%) anti-HCV positive, 1 (2.60%) anti-HTLV I/I positive, 1 (2.60%)
STS positive, and 1 (2.60%) HBsAg positive. Among the blood donors
with negative serology for anti-HIV, these markers were detected in 8,407
(10.50%), 441 (0.50%), 189 (0.20%), 464 (0.60%), and 473 (0.60%) of
samples, respectively. The difference was statistically significant (p <
0.001) for anti-HBc and anti-HCV, as determined by the Fisher Exact
Test (Table 2).
Table 1
Overall prevalence of the anti-HIV, anti-HBc, anti-HCV, anti-HTLV I/II
serologic markers, serologic tests for syphilis (STS), and HBsAg in 80,284
serum samples from blood donors of the Blood Bank of “Hospital Universitário
Regional Norte do Paraná”, Londrina, from July 1994 to April 2001
Serologic Marker Number of % Reactivity
Reactive (%)
Serum samples
Anti-HIV 39  0.05
Anti-HBc 8,419 10.50
Anti-HCV 451  0.56
Anti-HTLV I/II 190  0.24
Serologic test for syphilis (STS) 465  0.58
HBsAg 474  0.59
Anti-HIV: human immunodeficiency virus antibody; Anti-HBc: antibody to
hepatitis B virus core antigen; Anti-HCV: hepatitis C virus antibody; Anti-HTLV
I/II: human T-lymphotropic virus I and II antibodies; HBsAg: hepatitis B virus
surface antigen
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The sensitivity, PPV and RP of the surrogate markers assayed for
anti-HIV results are summarized in Table 3.
DISCUSSION
The anti-HBc reactivity obtained in this study (10.50%) was higher
when compared to that reported in blood donor screening surveys in the
United States6, 9,19, and to the seroprevalence of Brazil (average 8.65%),
but was lower than the rate of 14.06% registered among donors from the
southern region of Brazil14. The other overall prevalence rates of the
serologic surrogate markers for anti-HIV, anti-HTLV I/II, HBsAg, and
STS were higher when compared with the rates of five blood centers
within the United States and previous reported6,9. The rates of anti-HCV
and HBsAg were lower when compared with the rates registered among
Brazilian blood donors (1.22% and 0.97%, respectively)14 . Among the
39 anti-HIV seropositive donations, 12 (30.80%) were anti-HBc reactive,
which means that the sensitivity of anti-HBc in detecting an anti-HIV
seropositive donation was 30.80%. A total of 8,407 donations were anti-
HBc reactive but not anti-HIV seropositive, corresponding to a PPV of
0.10% (95% CI = 0.10 to 0.30%). The RP was 3.8, indicating that the
prevalence of anti-HIV positive results among anti-HBc reactive
donations was 3.8 times greater than that of anti-HIV-positive results
among anti-HBc nonreactive donations. The prevalence of infection with
hepatotropic viruses in an anti-HIV-reactive population from Argentina,
South America, was investigated and the results showed that the rates of
anti-HBc, HBsAg and anti-HCV (58.50%, 14.50% and 58.50%,
respectively) were significantly higher in anti-HIV-positive patients than
in the control group (3.20%, 0.50% and 1.00%, respectively), confirming
the high prevalence of HBV and HCV infections in HIV-positive patients
due to the occurrence of a common epidemiologic factor for the
acquisition of these viruses5.
Numerous reports have shown the importance of the maintenance of
anti-HBc in the routine of blood donor screening to help reduce the risk
of post-transfusion HBV infection and to serve as a surrogate marker
for HIV due to the overlapping epidemiology of HBV and HIV
infection1,11,12,17. During the evaluation of the risk of post-transfusion
infectious diseases17, it was verified that 6 donations made before anti-
HIV was detected were not used due the positivity of other serologic
surrogate markers such as elevated ALT (one donation), the presence of
HBsAg (one donation), anti-HBc reactivity (two donations), and auto-
exclusion (two donations). However, the maintenance of this test in
routine donor screening has been discussed in numerous studies. One of
them13, reported that 34.40% of donations were positive for anti-HBc,
but all of them were negative for HIV antigen p24. Moreover, 148 donors
had repeat testing for p24 6 to 8 months later and all remained negative.
When tested for anti-HBs, 95.70% were positive, indicating a state of
acquired immunity. The other 4.30% negative for anti-HBs all tested
negative for HBV-DNA and probably represented false-positive results,
a phenomenon well described with available anti-HBc tests. The results
indicated that adding the anti-HBc test to routine donor screening would
be unlikely to further reduce the risk of post-transfusion HBV and/or
HIV infection13.
The detection of anti-HBc reaction alone could be interpreted in
several ways, such as a false-positive result as a consequence of passive
transfer of antibodies from blood transfusion, the window period of HBV
Table 3
Sensitivity, positive predictive value, and relative prevalence of serologic surrogate markers for anti-HIV obtained in serum samples from blood donors of the
Blood Bank of “Hospital Universitário Regional Norte do Paraná”, Londrina, Brazil, from July 1994 to April 2001
Serologic Sensitivitya 95 % Positive 95 % Relative 95 %
surrogate (%) Confidence predictive Confidence prevalencec Confidence
marker interval valueb interval interval
Anti-HBc + 30.80 17.50 - 47.70 0.10 0.10 - 0.30 3.80 1.90 -007.50
Anti-HCV + 25.60 13.60 - 42.40 2.21 1.10 - 4.20 60.70 29.80 -123.80
Anti-HTLV+ 2.60 0.10 - 15.10 0.50 0.0 - 3.30 11.10 1.50 -080.40
STSd+ 2.60 0.10 - 15.10 0.20 0.0 - 1.40 4.50 0.60 -032.80
HBsAg+ 2.60 0.10 - 15.10 0.20 0.0 - 1.40 4.40 0.60 -032.20
a: % of reactive serologic surrogate marker donation among HIV-seropositive donations.; b: % of HIV-positive donations among reactive serologic surrogate marker
donations; c: Positive predictive value divided by %age of HIV-positive donations among negative serologic surrogate marker donations; d: Serologic test for syphilis
+: positive
Table 2
Prevalence of the surrogate markers anti-HBc, anti-HCV, anti-HTLV I/II,
serologic test for syphilis (STS) and HBsAg in anti-HIV reactive and anti-
HIV nonreactive serum samples from blood donors of the Blood Bank of
“Hospital Universitário Regional Norte do Paraná”, Londrina, Brazil, from
July 1994 to April 2001
Anti-HIV+ Anti-HIV –
Surrogate marker (n = 39) (n = 80.245) p* value
 n %  n %
Anti-HBc  12 30.80  8,407 10.50  <0.001
Anti-HCV  10 25.60  441 0.50  <0.001
Anti-HTLV I/II  1 2.60  189 0.20  0.088
STS  1 2.60  464 0.60  0.203
HBsAg  1 2.60  473 0.60  0.206
p value according to Fisher Exact Test (p<0.001); Anti-HIV +: human
immunodeficiency virus antibody reactive; Anti-HIV - : human
immunodeficiency virus antibody nonreactive; Anti-HBc: antibody to hepatitis
B virus core antigen; Anti-HCV: hepatitis C virus antibody; Anti-HTLV I/II:
human T-lymphotropic virus I and II antibodies; STS: Serologic test for syphilis;
HBsAg: hepatitis B virus surface antigen.
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infection, when anti-HBc is the only serologic marker detecting current
or past HBV infection7,8,16, and in cases of HVB variants when it is not
possible to detect the presence of HBsAg14.
As regards anti-HCV, among 39 anti-HIV-seropositive donations,
10 (25.60%) were anti-HCV reactive, which means that the sensitivity
of anti-HCV in detecting an anti-HIV-seropositive donation was 25.60%
(95% CI = 13.60 to 42.40%). There were 441 donations that were anti-
HCV reactive but not anti-HIV seropositive, resulting in a PPV of 2.21%
(95% CI = 1.10 to 4.20%). The RP was 60.70, indicating that the
prevalence of anti-HIV-positive results among anti-HCV-reactive
donations was 60.7 times higher than that of anti-HIV-positive results
among anti-HCV nonreactive donations.
STS in screening of blood donors has been maintained, in part, to
identify and remove from the blood supply donations from persons at
risk for HIV infection. Some authors related that the STS could indirectly
prevent the residual risk of HIV transmission15. However, other studies
demonstrated a low PPV of the STS for the HIV infection (0.06%),
suggesting that this screening prevents the transfusion of few HIV
infectious window-period donations6. Our results did not show the
importance of STS as a surrogate marker for HIV infection. Its sensitivity
was 2.60% (95% CI = 0.10 to 15.10%), PPV was 0.20% (95% CI = 0.0
to 1.40%), and RP 4.5, which means that the prevalence of anti-HIV-
positive results among STS-reactive donations was 4.5 times higher than
that of anti-HIV-positive results among STS-nonreactive donations. These
results confirmed that the STS screening is a poor marker and a costly
strategy for preventing post-screening HIV infections and other blood-
borne diseases, preventing the transfusion of few HIV infections window-
period donations2.
Although the present results for anti-HTLVI/II were not statistically
significant for its use as a surrogate marker for HIV infection, the RP
obtained of 11.10 (95% CI = 1.50 to 80.40%) indicated that the prevalence
of anti-HIV-positive results among anti-HTLV I/II-reactive donations
was 11.1 times greater than that of anti-HIV-positive results among anti-
HTLV I/II nonreactive donations.
HTLV I/II share the same modes of transmission and risk factors as
HIV. Thus, an overlap in exposure to these retroviruses is expected. The
evaluation of the seroprevalence of HTLV I/II infections and their risk
factors in HIV-seropositive individuals in Santos, São Paulo (Brazil)
revealed an independent association of HTLV I/II infection with
intravenous drug use and HCV seropositivity and the results indicated
that HIV-infected individuals are at high and similar risk to be exposed
to HTLV I/II infections4.
The low PPV obtained for all the surrogate markers for HIV infection
evaluated is explained in part by the low rates of seroprevalence of this
retroviral infection (0.05%) among the blood donors included in this
study. Other factors could be the sensitivity and the specificity of the
methods assayed to detected the surrogate markers. Lack of specificity
in the detection of these surrogate markers for anti-HIV creates significant
numbers of false-positive results and contributes to the low VPP, resulting
in problems for the donor and blood banking community, such as unit
loss, donor loss, unnecessary apprehension, and medical follow-up for
the donors. Although the predictive positive value for these surrogate
markers were low for HIV infection, the results confirmed the anti-HBc
and anti-HCV as useful surrogate markers for HIV infection and
reinforcing the maintenance of them in the screening for blood donors
contributing, in part, to the prevention of the small number of cases in
which HIV that is still transmitted by transfusion. The results also
reinforce the importance of the clinical and laboratory follow-up of the
blood donors with reactivity of these surrogate markers, even without
symptoms, in order to detect other infectious agents. As regard to HIV
infection, efforts should be focused on other strategies to reduce the risk
of post-transfusion of this retroviral infection. The introduction of HIV
p24 antigen tests and the nucleic acid amplification techniques such as
the polymerase chain reaction, are suitable methods to close the diagnostic
window in blood donation screening. The introduction of these new
tests in the routine serological screening also in developing countries,
should be possible to increase the sensitivity of HIV diagnosis so that
fewer donations will be overlooked in the diagnostic window phase and,
in this way, the effectiveness of blood donor screening and the safety of
the blood components will be significantly improved.
RESUMO
Avaliação dos marcadores indiretos na infecção pelo vírus da
imunodeficiência humana (HIV) entre doadores de sangue do
hemocentro do “Hospital Universitário Regional Norte do
Paraná”, Londrina, PR, Brasil
Este estudo avaliou a utilidade dos testes sorológicos para pesquisa
de anticorpos anti-antígeno “core” do vírus da hepatite B (anti-HBc),
anti-vírus da hepatite C (anti-HCV), anti-vírus linfotrópico de células T
humanas tipos I e II (anti-HTLV I/II), testes sorológicos para sífilis e
pesquisa do antígeno de superfície do vírus da hepatite B (HBsAg) como
marcadores sorológicos indiretos do risco de infecção pelo vírus da
imunodeficiência humana (HIV) em 80.284 amostras de soro de doadores
de sangue do Hemocentro do Hospital Universitário Regional Norte do
Paraná, Londrina, do período de julho de 1994 a abril de 2001. Entre 39
doadores de sangue com sorologia positiva para HIV, 12 (30,8%)
apresentaram anti-HBc, 10 (25,6%) anti-HCV, 1 (2,6%) anti-HTLV I/II,
1 (2,6%) sorologia reagente para sífilis, e 1 (2,6%) a presença de HBsAg.
Entre os doadores com sorologia negativa para HIV, estes marcadores
foram detectados em 8.407 (10,5%), 441 (0,5%), 189 (0,2%), 464 (0,6%),
e 473 (0,6%) amostras, respectivamente. A diferença foi estatisticamente
significativa (p < 0,001) para anti-HBc e anti-HCV. Embora o valor
preditivo positivo para estes marcadores para a infecção pelo HIV foi
baixo, os resultados confirmam a importância do anti-HBc e o anti-HCV
como marcadores indiretos úteis da infecção por HIV em doadores de
sangue e reforçam a sua manutenção na triagem sorológica dos doadores
de sangue contribuindo para a prevenção do pequeno número de casos
em que o HIV é ainda transmitido por transfusão.
REFERENCES
1. BASSIT, L.; SAEZ-ALQUEZAR, A.; ROMANO, C.C. et al. - Estudo comparativo entre
anti-HIV e anti-HBc em doadores de sangue na Fundação Pró-Sangue Hemocentro
de São Paulo. Bol. Soc. bras. Hemat. Hemot., 16(165): 133, 1994.
2. CASE, J. - Serologic test for syphilis: a discredited surrogate test for HIV infection.
Letter. Transfusion, 38: 218, 1998.
3. CHOO, Q.L.; KUO, G.; WEINER, A.J. et al. - Isolation of a cDNA clone derived from a
blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359-362, 1989.
REICHE, E.M.V.; VOGLER, I.H.; MORIMOTO, H.K.; BORTOLIERO, A.L.; MATSUO, T.; YUAHASI, K.K.; CANCIAN, S.J. & KOGUICHI, R.S. - Evaluation of surrogate markers for
human immunodeficiency virus infection among blood donors at the blood bank of “Hospital Universitário Regional Norte do Paraná”, Londrina, PR, Brazil. Rev. Inst. Med. trop. S.
Paulo, 45(1):23-27, 2003.
27
4. ETZEL, A. - Infecção pelos vírus linfotrópicos de células T humanas dos tipos I
(HTLV I) e II (HTLV II) em portadores do HIV em Santos-SP: estudo de
prevalência e fatores de risco. São Paulo, 1999. (Dissertação de Mestrado - Faculdade
de Medicina da Universidade de São Paulo).
5. FAINBOIM, H.; GONZALEZ, J.; FASSIO, E. et al. - Prevalence of hepatitis viruses in
an anti-human immunodeficiency virus-positive population from Argentina. A
multicentre study. J. viral Hepatitis, 6: 53-57, 1999.
6. HERRERA, G.A.; LACKRITZ, E.N.; JANSSEN, R.S. et al. - Serologic test for syphilis
as a surrogate marker for human immunodeficiency virus infection among United
States blood donors. Transfusion, 37:  836-840, 1997.
7. INOUYE, M.M.Z.; REICHE, E.M.V. & PONTELLO, R. - Marcadores sorológicos da
hepatite por vírus B (HBV): a detecção de anti-HBcAg em indivíduos HBsAg
negativos como sinal de alerta na hepatite por vírus B pós-transfusional. Semina
(Londrina), 13: 102-104, 1992.
8. KATCHAKI, J.N.; BROUWER, R. & SIEM, T.H. - Anti-HBc and blood infectivity.
New Engl. J. Med., 298: 1421-1422, 1978.
9. KORELITZ, J.J.; BUSCH, M.P.; KLEINMAN, S.H. et al. - Relationship between antibody
to hepatitis B core antigen and retroviral infections in blood from volunteer donors.
Transfusion, 36: 232-237, 1996.
10. LACKRITZ, E.M. - Prevention of HIV transmission by blood transfusion in the developing
world: achievements and continuing challenges. AIDS, 12 (suppl. A): S81-S86, 1998.
11. LACKRITZ, E.M.; SATTEN, G.A.; ABERLE-GRASSE, J. et al. - Estimated risk of
transmission of the human immunodeficiency virus by screened blood in the United
States. New Engl. J. Med., 333: 1721-1725, 1995.
12. LEITMAN, S.F.; KLEIN, H.G.; MELPOLDER, J.J. et al. - Clinical implications of positive
tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood
donors. New Engl. J. Med., 321: 917-924, 1989.
13. MAHMOUD, M.Y.; EL-TAHAWY, M.A.; ZAKI, A.M. et al. - Value of anti-HBc in
donor screening. Brit. J. Haemat., 105 (suppl.1): 50, 1999.
14.  SÁEZ-ALQUÉZAR, A.; BASSIT, L. & SABINO, E.C. - Hepatites virais. In: FERREIRA,
A.W. & ÁVILA, S.M., ed. Diagnóstico laboratorial das principais doenças
infecciosas e auto-imunes. 2. ed. Rio de Janeiro, Guanabara Koogan, 2001. p. 74-
91.
15. SÁEZ-ALQUÉZAR, A.; SALES, N.A. & CHAMONE, D.A.F. - Triagem sorológica em
bancos de sangue. In: VERONESI, R. & FOCACCIA, R., ed. Tratado de
Infectologia. São Paulo, Atheneu, 1997. p. 1743-1751.
16. SARNO, E.N.; ALVARIZ, F.G.; SILVA, D.B.; RUZANY, F. & PEREIRA, J.L. - “Anti-
core” como indicação de infecção pelo vírus B da hepatite. Rev. Inst. Med. trop. S.
Paulo, 19: 374-377,1977.
17. SCHREIBER, G.B.; BUSCH, M.P.; KLEINMAN, S.H. & KORELITZ, J.J. - The risk of
transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.
New Engl. J. Med., 334: 1685-1690, 1996.
18. SEGURADO, A.A.C. - Infecção por HTLV I e HTLV II. In: FERREIRA, A.W. & ÁVILA,
S.M. Diagnóstico laboratorial das principais doenças infecciosas e auto-imunes.
2. ed. Rio de Janeiro, Guanabara Koogan, 2001. p. 103-110.
19. WALLACH, J. - Interpretação de exames de laboratório. 6. ed. Rio de Janeiro, Ed.
Médica e Científica, 1999. p. 220-230.
20. WEARE, J.A.; ROBERTSON, E.F.; MADSEN, G.; HU, R. & DECKER, R.H. -
Improvement in the specificity of assays for detection of antibody to hepatitis B core
antigen. J. clin. Microbiol., 29: 600-604, 1991.
Received: 10 May 2002
Accepted: 03 October 2002
